Mar 10, 2025
Glycogen Synthase Kinase 3 (GSK-3) and Suicide: A Systematic Review
- 1Faculdade de Medicina de São José do Rio Preto
Protocol Citation: Juliano Flávio Rubatino Rodrigues 2025. Glycogen Synthase Kinase 3 (GSK-3) and Suicide: A Systematic Review. protocols.io https://dx.doi.org/10.17504/protocols.io.e6nvwbx8zvmk/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol, and it's working. We research Pubmed, Lilacs, and Embase. At this moment, we will identify papers. After that, we will include paper, extract the data and published results.
Created: March 10, 2025
Last Modified: March 10, 2025
Protocol Integer ID: 124114
Abstract
Introduction
Glycogen synthase kinase 3 (GSK-3) has been associated with a lot of diseases, such as Alzheimer’s Disease and diabetes. Its role in depression is connected to stress and neuroinflammation. Lithium is an essential inhibitor of GSK-3. Some studies have suggested that the use of this psychiatric medication may lower suicide rates. Here, we outline the current understanding and discoveries regarding the link between GSK-3 and suicide.
Method
We used the PRISMA statement and defined the PECOS strategy, such as Population (P) = individuals; exposure (E) = GSK-3 alteration function; comparison (C) = without GSK-3 alteration function; outcome (O) = suicide; and study design(S) = all kinds of studies with an association between GSK-3 and suicide. It was search on Pubmed, Lilacs and Embase in March, 2025.
Glycogen Synthase Kinase 3 (GSK-3) and Suicide: A Systematic Review
Glycogen Synthase Kinase 3 (GSK-3) and Suicide: A Systematic Review
Glycogen synthase kinase 3(GSK-3) has been associated with a lot of diseases, such as Alzheimer’s Disease and diabetes. Its role in depression is connected to stress and neuroinflammation. Lithium is an essential inhibitor of GSK-3. Some studies have suggested that the use of this psychiatric medication may lower suicide rates. Here, we outline the current understanding and discoveries regarding thelink between GSK-3 and suicide.
We used the PRISMA statement and defined the PECOS strategy, such as Population (P) = individuals; exposure (E) = GSK-3 alteration function; comparison (C) = without GSK-3 alteration function; outcome (O) = suicide; and study design(S) = all kinds of studies with an association between GSK-3 and suicide.